201 related articles for article (PubMed ID: 33531153)
1. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Rousseau A; Thieblemont C
Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
[No Abstract] [Full Text] [Related]
2. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
[No Abstract] [Full Text] [Related]
4. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
5. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Mian A; Hill BT
Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715
[No Abstract] [Full Text] [Related]
6. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
Fileni C; Sarkozy C
Bull Cancer; 2023 Oct; 110(10):988-990. PubMed ID: 37658026
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
Marchetti M; Visco C
Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
[TBL] [Abstract][Full Text] [Related]
8. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
9. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
10. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
11. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
12. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
McCulloch R
Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
[TBL] [Abstract][Full Text] [Related]
13. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Munoz JL; Wang Y; Jain P; Wang M
Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
[No Abstract] [Full Text] [Related]
15. Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.
Minson A; Dickinson M
Leuk Lymphoma; 2024 May; 65(5):546-547. PubMed ID: 38420955
[No Abstract] [Full Text] [Related]
16. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
17. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jimenez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Nunes A; Reitan J; Wade SW; Salles G
Leuk Lymphoma; 2024 Jan; 65(1):14-25. PubMed ID: 37840282
[TBL] [Abstract][Full Text] [Related]
18. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
McCulloch R; Eyre TA; Rule S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
[TBL] [Abstract][Full Text] [Related]
19. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
Anderson MK; Torosyan A; Halford Z
Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
